title: Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
abstract: OBJECTIVE
  To examine the psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scales (CYBOCS) modified for pervasive developmental disorders (PDDs).
  
  
  METHODS
  Raters from five Research Units on Pediatric Psychopharmacology (RUPP) Autism Network were trained to reliability. The modified scale (CYBOCS-PDD), which contains only the five Compulsion severity items (range 0-20), was administered to 172 medication-free children (mean 8.2 +/- 2.6 years) with PDD (autistic disorder, n = 152; Asperger's disorder, n = 6; PDD not otherwise specified, n = 14) participating in RUPP clinical trials. Reliability was assessed by intraclass correlation coefficient (ICC) and internal consistency by Cronbach's alpha coefficient. Correlations with ratings of repetitive behavior and disruptive behavior were examined for validity.
  
  
  RESULTS
  Eleven raters showed excellent reliability (ICC = 0.97). The mean CYBOCS score was 14.4 (+/- 3.86) with excellent internal consistency (alpha = .85). Correlations with other measures of repetitive behavior ranged from r = 0.11 to r = 0.28 and were similar to correlations with measures of irritability (r = 0.24) and hyperactivity (r = 0.25). Children with higher scores on the CYBOCS-PDD had higher levels of maladaptive behaviors and lower adaptive functioning.
  
  
  CONCLUSIONS
  The five-item CYBOCS-PDD is reliable, distinct from other measures of repetitive behavior, and sensitive to change.
authors.affiliation: Yale Child Study Center, Yale University, New Haven, CT 06520, USA. lawrence.scahill@yale.edu
authors.forename: Lawrence
authors.initials: L
authors.lastname: Scahill
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: McDougle
authors.forename: Susan K
authors.initials: SK
authors.lastname: Williams
authors.forename: Anastasia
authors.initials: A
authors.lastname: Dimitropoulos
authors.forename: Michael G
authors.initials: MG
authors.lastname: Aman
authors.forename: James T
authors.initials: JT
authors.lastname: McCracken
authors.forename: Elaine
authors.initials: E
authors.lastname: Tierney
authors.forename: L Eugene
authors.initials: LE
authors.lastname: Arnold
authors.forename: Pegeen
authors.initials: P
authors.lastname: Cronin
authors.forename: Marco
authors.initials: M
authors.lastname: Grados
authors.forename: Jaswinder
authors.initials: J
authors.lastname: Ghuman
authors.forename: Kathleen
authors.initials: K
authors.lastname: Koenig
authors.forename: Kristen S L
authors.initials: KS
authors.lastname: Lam
authors.forename: James
authors.initials: J
authors.lastname: McGough
authors.forename: David J
authors.initials: DJ
authors.lastname: Posey
authors.forename: Louise
authors.initials: L
authors.lastname: Ritz
authors.forename: Naomi B
authors.initials: NB
authors.lastname: Swiezy
authors.forename: Benedetto
authors.initials: B
authors.lastname: Vitiello
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D015203:Reproducibility of Results; D018967:Risperidone / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D018967:Risperidone